GlassScriptPhysician profile
Song H Na
NPI 1851440127
$7,584.63
in general payments reported to CMS, 2019-2025
52 companies · $598 in 2025
The $598 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $1,260 · 2021: $1,559 · 2022: $1,451 · 2023: $1,162 · 2024: $860 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,620.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $930.30 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $775.60 | 2019-2024 | |
| Abbvie INC. | $727.00 | 2019-2025 | |
| Lilly USA, LLC | $650.76 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $559.43 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $513.93 | 2019-2022 | |
| Glaxosmithkline, LLC. | $408.60 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $351.43 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $284.63 | 2020-2023 | Spravato |
| Astellas Pharma US INC | $271.89 | 2019-2025 | Veozah |
| Amgen INC. | $246.56 | 2019-2025 | Otezla, Repatha, Repatha |
| Eisai INC. | $193.48 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $143.22 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.80 | 2020-2022 | |
| Exact Sciences Corporation | $118.39 | 2023-2025 | Cologuard Collection Kit |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Song Na listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.